A participant died in a clinical trial of a Federal Drug Administration-approved antibody treatment for Alzheimer’s disease, and the death may be linked to the drug, a new case report reveals. The case, published in May in the Journal of Alzheimer’s Disease, details unreported adverse outcomes associated with the use of Lecanemab (Lequembi), an anti-amyloid…
2 Fast-Approved Anti-Amyloid Alzheimer’s Drugs Raise Concerns
Over the past two years, two Alzheimer’s disease drugs were approved under accelerated approval. Both drugs are based on popular amyloid beta-plaque theories, yet both have raised questions. On Jan. 6, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb), a new monoclonal antibody that seems to slow cognitive decline in some Alzheimer’s patients. In…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`